Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Metastatic Urothelial Cancer and Other Solid Tumors
NCT02091999Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2014
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of enfortumab vedotin in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), ovarian cancer and 1 more (5 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of adverse events up to 36 months, Concentration at the end of infusion and 7 more. Started May 2014; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT02091999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091999.